Morgan Stanley’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-1,092,482
| Closed | -$78.8M | – | 8468 |
|
|
2025
Q4 | $78.8M | Buy |
1,092,482
+400,970
| +58% | +$25.9M | ﹤0.01% | 1656 |
|
|
2025
Q3 | $30.1M | Buy |
691,512
+245,632
| +55% | +$9.93M | ﹤0.01% | 2479 |
|
|
2025
Q2 | $12.7M | Sell |
445,880
-79,816
| -15% | -$2.38M | ﹤0.01% | 3223 |
|
|
2025
Q1 | $15.5M | Sell |
525,696
-688,080
| -57% | -$21.4M | ﹤0.01% | 2944 |
|
|
2024
Q4 | $35.3M | Buy |
1,213,776
+602,539
| +99% | +$25.2M | ﹤0.01% | 2166 |
|
|
2024
Q3 | $28.1M | Sell |
611,237
-642,997
| -51% | -$27.9M | ﹤0.01% | 2447 |
|
|
2024
Q2 | $51.2M | Sell |
1,254,234
-283,062
| -18% | -$8.12M | ﹤0.01% | 1734 |
|
|
2024
Q1 | $39.2M | Sell |
1,537,296
-1,444,190
| -48% | -$22.6M | ﹤0.01% | 1982 |
|
|
2023
Q4 | $27M | Buy |
2,981,486
+1,823,904
| +158% | +$12.2M | ﹤0.01% | 3082 |
|
|
2023
Q3 | $7.39M | Buy |
1,157,582
+58,987
| +5% | +$508K | ﹤0.01% | 3399 |
|
|
2023
Q2 | $12.2M | Sell |
1,098,595
-153,867
| -12% | -$1.93M | ﹤0.01% | 2977 |
|
|
2023
Q1 | $19.2M | Buy |
1,252,462
+227,610
| +22% | +$5.01M | ﹤0.01% | 2477 |
|
|
2022
Q4 | $22.7M | Buy |
1,024,852
+944,272
| +1,172% | +$14.1M | ﹤0.01% | 2207 |
|
|
2022
Q3 | $1.31M | Sell |
80,580
-53,649
| -40% | -$1.03M | ﹤0.01% | 4718 |
|
|
2022
Q2 | $1.95M | Buy |
134,229
+24,857
| +23% | +$370K | ﹤0.01% | 4561 |
|
|
2022
Q1 | $2.02M | Buy |
109,372
+34,555
| +46% | +$587K | ﹤0.01% | 4522 |
|
|
2021
Q4 | $1.78M | Sell |
74,817
-48,020
| -39% | -$1.15M | ﹤0.01% | 4672 |
|
|
2021
Q3 | $3.03M | Buy |
122,837
+20,654
| +20% | +$449K | ﹤0.01% | 4219 |
|
|
2021
Q2 | $2.52M | Sell |
102,183
-54,357
| -35% | -$1.26M | ﹤0.01% | 4457 |
|
|
2021
Q1 | $3.41M | Buy |
156,540
+89,317
| +133% | +$2.19M | ﹤0.01% | 3805 |
|
|
2020
Q4 | $1.72M | Buy |
67,223
+62,178
| +1,232% | +$1.81M | ﹤0.01% | 4282 |
|
|
2020
Q3 | $142K | Buy |
+5,045
| New | +$146K | ﹤0.01% | 5268 |
|
Other funds holding RNAM
Morgan Stanley's RNAM Position: Q1 2026 in Review
Morgan Stanley sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 1,092,482 shares — an estimated $78.8M sold.
Morgan Stanley first reported a position in RNAM in Q3 2020 and held it in 22 quarters. The position peaked at $78.8M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Morgan Stanley reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Morgan Stanley sold 1,092,482 Avidity Biosciences shares in Q1 2026, an estimated $78.8M.
- Morgan Stanley first reported a position in Avidity Biosciences in Q3 2020 and held it in 22 quarters.
- Morgan Stanley's Avidity Biosciences position peaked at $78.8M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.